Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label follow-up study of sarizotan in Parkinson's disease with treatment-associated dyskinesia
2005-000444-84Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sarizotan in Parkinson's disease (PD), sponsored by Merck KGaA. Primary endpoints: Long-term safety summary, Long-term efficacy summary and 1 more. Started May 2005; status: terminated.
02
Drugs
sarizotan
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-000444-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000444-84.